A compound of formula wherein Ris H or -(C 1 -C 4)alkyl; L is selected from the group consisting of -CH 2 - and -C -; Li is selected from the group consisting of -C NH- and -NHC -; Hy is a bicyclic heteroaryl optionally substituted by one or more groups selected from -(C 1 -C 4)alkyl, heterocycloalkyl and -(C 1 -C 4)alkylene-NR A R B, or Hy is a bicyclic semi saturated heteroaryl; R A is H or -(C 1 -C 4)alkyl; R B is H or -(C 1 -C 4)alkyl; R 1 is selected from the group consisting of: - Het which is a heteroaryl optionally substituted by one or more groups selected from -(C 1 -C 4)alkyl, -(C 1 -C 4)haloalkyl, -(C 1 -C 4)alkylene-heterocycloalkyl-NR A R B, - (C 1 -C 4)alkylene-NR A R B and aryl, wherein said aryl is optionally substituted by one or more -(C 1 -C 4)alkyl, and - X wherein R 2 is selected from the group consisting of -O(C 1 -C 4)haloalkyl, halogen atoms and -(C 1 -C 4)haloalkyl; R 3 is H or is selected from the group consisting of -O(C 1 -C 4)alkyl, -C NH-(C 1 -C 4)alkylene-NR A R B, -C -heterocycloalkyl, wherein said heterocycloalkyl is optionally substituted by one or more -(C 1 -C 4)alkyl, -O-heterocycloalkyl, wherein said heterocycloalkyl is optionally substituted by one or more -(C 1 -C 4)alkyl, -O(Ci-C 4)alkylene-heterocycloalkyl, -(C 1 -C 4)alkylene-NR A R B, heteroaryl optionally substituted by one or more -(C 1 -C 4)alkyl, and monocyclic heterocycloalkyl-(C 1 -C 4)alkylene-, wherein said heterocycloalkyl is optionally substituted by one or more groups selected from -(C 1 -C 4)alkyl and -NR A R B; and pharmaceutically acceptable salts thereof. Ris H or -(C 1 -C 4)alkyl; L is selected from the group consisting of -CH 2 - and -C -; Li is selected from the group consisting of -C NH- and -NHC -; Hy is a bicyclic heteroaryl optionally substituted by one or more groups selected from -(C 1 -C 4)alkyl, heterocycloalkyl and -(C 1 -C 4)alkylene-NR A R B, or Hy is a bicyclic semi saturated heteroaryl; R A is H or -(C 1 -C 4)alkyl; R B is H or -(C 1 -C 4)alkyl; R 1 is selected from the group consisting of: - Het which is a heteroaryl optionally substituted by one or more groups selected from -(C 1 -C 4)alkyl, -(C 1 -C 4)haloalkyl, -(C 1 -C 4)alkylene-heterocycloalkyl-NR A R B, - (C 1 -C 4)alkylene-NR A R B and aryl, wherein said aryl is optionally substituted by one or more -(C 1 -C 4)alkyl, and - X wherein R 2 is selected from the group consisting of -O(C 1 -C 4)haloalkyl, halogen atoms and -(C 1 -C 4)haloalkyl; R 3 is H or is selected from the group consisting of -O(C 1 -C 4)alkyl, -C NH-(C 1 -C 4)alkylene-NR A R B, -C -heterocycloalkyl, wherein said heterocycloalkyl is optionally substituted by one or more -(C 1 -C 4)alkyl, -O-heterocycloalkyl, wherein said heterocycloalkyl is optionally substituted by one or more -(C 1 -C 4)alkyl, -O(Ci-C 4)alkylene-heterocycloalkyl, -(C 1 -C 4)alkylene-NR A R B, heteroaryl optionally substituted by one or more -(C 1 -C 4)alkyl, and monocyclic heterocycloalkyl-(C 1 -C 4)alkylene-, wherein said heterocycloalkyl is optionally substituted by one or more groups selected from -(C 1 -C 4)alkyl and -NR A R B; and pharmaceutically acceptable salts thereof. - Het which is a heteroaryl optionally substituted by one or more groups selected from -(C 1 -C 4)alkyl, -(C 1 -C 4)haloalkyl, -(C 1 -C 4)alkylene-heterocycloalkyl-NR A R B, - (C 1 -C 4)alkylene-NR A R B and aryl, wherein said aryl is optionally substituted by one or more -(C 1 -C 4)alkyl, and - X wherein R 2 is selected from the group consisting of -O(C 1 -C 4)haloalkyl, halogen atoms and -(C 1 -C 4)haloalkyl; R 3 is H or is selected from the group consisting of -O(C 1 -C 4)alkyl, -C NH-(C 1 -C 4)alkylene-NR A R B, -C -heterocycloalkyl, wherein said heterocycloalkyl is optionally substituted by one or more -(C 1 -C 4)alkyl, -O-heterocycloalkyl, wherein said heterocycloalkyl is optionally substituted by one or more -(C 1 -C 4)alkyl, -O(Ci-C 4)alkylene-heterocycloalkyl, -(C 1 -C 4)alkylene-NR A R B, heteroaryl optionally substituted by one or more -(C 1 -C 4)alkyl, and monocyclic heterocycloalkyl-(C 1 -C 4)alkylene-, wherein said heterocycloalkyl is optionally substituted by one or more groups selected from -(C 1 -C 4)alkyl and -NR A R B; and pharmaceutically acceptable salts thereof. wherein R 2 is selected from the group consisting of -O(C 1 -C 4)haloalkyl, halogen atoms and -(C 1 -C 4)haloalkyl; R 3 is H or is selected from the group consisting of -O(C 1 -C 4)alkyl, -C NH-(C 1 -C 4)alkylene-NR A R B, -C -heterocycloalkyl, wherein said heterocycloalkyl is optionally substituted by one or more -(C 1 -C 4)alkyl, -O-heterocycloalkyl, wherein said heterocycloalkyl is optionally substituted by one or more -(C 1 -C 4)alkyl, -O(Ci-C 4)alkylene-heterocycloalkyl, -(C 1 -C 4)alkylene-NR A R B, heteroaryl optionally substituted by one or more -(C 1 -C 4)alkyl, and monocyclic heterocycloalkyl-(C 1 -C 4)alkylene-, wherein said heterocycloalkyl is optionally substituted by one or more groups selected from -(C 1 -C 4)alkyl and -NR A R B; and pharmaceutically acceptable salts thereof.